Clinical Pharmacogenetic Study of Sorafenib in Egyptian Patients With Hepatocellular Carcinoma
NCT ID: NCT06527495
Last Updated: 2024-07-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE1/PHASE2
150 participants
INTERVENTIONAL
2023-01-01
2024-12-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Sorafenib In Egyptian Patients With Hepatocellular Carcinoma.
NCT06030895
Sorafenib Versus Best Supportive Care in Egyptian Hepatocellular Carcinoma Patients.
NCT02971696
Pharmacogenetic Study in Hepatocellular Carcinoma Patients.
NCT05291338
Sorafenib Plus Tegafur-uracil (UFT) Versus Sorafenib as First Line Systemic Treatment for Patients With Advanced Stage HCC, Unresectable & Not Eligible for Local Ablation and/or TACE
NCT01539018
4SC-201 (Resminostat) and Sorafenib in Advanced Hepatocellular Carcinoma
NCT00943449
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Sorafenib
Sorafenib 200 - 400 mg twice daily
Sorafenib
Sorafenib Tablets (200 -400 mg) twice daily
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Sorafenib
Sorafenib Tablets (200 -400 mg) twice daily
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* All patients with hepatocellular carcinoma will be included in group I.
* Patients not treated with systemic TKIs
Exclusion Criteria
* Patients with Child-Pugh grade C for liver function.
* Patients with other malignancies.
* Patients with chronic inflammatory disorders.
* Patients with severe organ dysfunction such as heart, lung, and kidney.
* Patients who cannot tolerate or are allergic to sorafenib.
* Patients with severe coagulation dysfunction were uncorrectable.
* Age less than 18 years old.
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Assiut University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Mahmoud Nazih
Principal Investigator
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
NLI
Shibīn al Kawm, Menoufia, Egypt
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
00470/2023
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.